UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported) January 13, 2000
Salix Pharmaceuticals, Ltd.
(Exact name of registrant as specified in its charter)
British Virgin Islands 000-23265 94-3267443
(State of other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
3600 West Bayshore Road, Palo Alto, California 94303
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 849-5900
Not applicable
(Former name or former address, if changed since last report.)
ITEM 5. OTHER EVENTS.
Attached as Exhibit 99.1 is a press release issued by Salix
Pharmaceuticals, Ltd., dated January 17, 2000, announcing that its Board
has adopted a Shareholder Protection Rights Agreement containing minor
revisions to the one it adopted, but did not implement, in November
1998.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) EXHIBITS
10.24 Shareholder Protection Rights Agreement, dated as of January
13, 2000 between Salix Pharmaceuticals, Ltd. and Montreal
Trust Company of Canada.
99.1 Press Release dated January 17, 2000
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 18, 2000
Salix Pharmaceuticals, Ltd.
By: /s/ Robert P. Ruscher
Robert P. Ruscher
President and Chief Executive Officer
3
EXHIBIT INDEX
Exhibit
Number Description
- ------ -----------
10.24 Shareholder Protection Rights Agreement, dated as of January 13,
2000 between Salix Pharmaceuticals, Ltd. and Montreal Trust Company
of Canada.
99.1 Press Release dated January 17, 2000
4